The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment

Eye

Volumn 25, Issue 2, 2011, Pages 127-139

  Wang, Y ^a,b   Wang, V M ^a   Chan, C C ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

age related macular degeneration; biologics; corticosteroid; immunosuppressant; inflammation; nonsteoridal anti inflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ARC 1905; BEVACIZUMAB; BROMFENAC; CHEMOKINE; COMPLEMENT; COMPLEMENT INHIBITOR; CORTICOSTEROID; CYTOKINE; DACLIZUMAB; DEXAMETHASONE; DICLOFENAC; ECULIZUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; KETOROLAC; METHOTREXATE; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE; RANIBIZUMAB; RAPAMYCIN; TNX 234; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CATARACT; COMPLEMENT SYSTEM; CORNEA DISEASE; DEMYELINATING DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG SAFETY; EYE INFLAMMATION; EYE TOXICITY; HUMAN; IMMUNOPATHOGENESIS; INFECTION; INTRAOCULAR PRESSURE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY; TUBERCULOSIS; UVEITIS; VISUAL ACUITY;

EID: 79951561948     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2010.196     Document Type: Review

References (107)

1. World Health Organization. Visual impairment and blindness. 2009. Available at http://www.who.int/mediacentre/factsheets/fs282/en/index.html. Accessed 9 October 2010.
2. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-572. (Pubitemid 38456293)
3. Coleman HR, Chan CC, Ferris III FL, Chew EY. Age-related macular degeneration. Lancet 2008; 372: 1835-1845.
4. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-1642. (Pubitemid 15204559)
5. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007; 114: 253-262. (Pubitemid 46161820)
6. Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Javier Nieto F, Huang GH et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol 2010; 128: 750-758.
7. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009; 28: 1-18.
8. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol 2008; 30: 97-110.
9. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-389. (Pubitemid 40530070)
10. Sivaprasad S, Adewoyin T, Bailey TA, Dandekar SS, Jenkins S, Webster AR et al. Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol 2007; 125: 515-519. (Pubitemid 46596724)
11. Dastgheib K, Green WR. Granulomatous reaction to Bruch's membrane in age-related macular degeneration. Arch Ophthalmol 1994; 112: 813-818. (Pubitemid 24180520)
12. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001; 29: 188-192. (Pubitemid 32618988)
13. Apte RS. Regulation of angiogenesis by macrophages. Adv Exp Med Biol 2010; 664: 15-19.
14. Langmann T. Microglia activation in retinal degeneration. J Leukoc Biol 2007; 81: 1345-1351. (Pubitemid 46827958)
15. Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp Eye Res 2003; 76: 463-471. (Pubitemid 36299058)
16. Penfold PL, Provis JM, Furby JH, Gatenby PA, Billson FA. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1990; 228: 270-274. (Pubitemid 20150313)
17. Gu X, Meer SG, Miyagi M, Rayborn ME, Hollyfield JG, Crabb JW et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 2003; 278: 42027-42035. (Pubitemid 37310467)
18. Morohoshi K, Goodwin AM, Ohbayashi M, Ono SJ. Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. J Autoimmun 2009; 33: 247-254.
19. Haas P, Steindl K, Schmid-Kubista KE, Aggermann T,Krugluger W, Hageman GS et al. Complement factor H gene polymorphisms and Chlamydia pneumoniae infection in age-related macular degeneration. Eye (Lond) 2009; 23: 2228-2232.
20. Shen D, Tuo J, Patel M, Herzlich AA, Ding X, Chew EY et al. Chlamydia pneumoniae infection, complement factor H variants and age-related macular degeneration. Br J Ophthalmol 2009; 93: 405-408.
21. Kalayoglu MV, Miller JW. Infection, inflammation and age-related macular degeneration. Clin Experiment Ophthalmol 2007; 35: 3-4. (Pubitemid 46195920)
22. Guymer R, Robman L. Chlamydia pneumoniae and age-related macular degeneration: a role in pathogenesis or merely a chance association? Clin Experiment Ophthalmol 2007; 35: 89-93. (Pubitemid 46195934)
23. Fujimoto T, Sonoda KH, Hijioka K, Sato K, Takeda A, Hasegawa E et al. Choroidal neovascularization enhanced by Chlamydia pneumoniae via Toll-like receptor 2 in the retinal pigment epithelium. Invest Ophthalmol Vis Sci 2010; 51: 4694-4702.
24. Baird PN, Robman LD, Richardson AJ, Dimitrov PN, Tikellis G, McCarty CA et al. Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection. Hum Mol Genet 2008; 17: 1299-1305. (Pubitemid 351566966)
25. Miller DM, Espinosa-Heidmann DG, Legra J, Dubovy SR, Suner IJ, Sedmak DD et al. The association of prior cytomegalovirus infection with neovascular age-related macular degeneration. Am J Ophthalmol 2004; 138: 323-328. (Pubitemid 39208558)
26. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog Retin Eye Res 2009; 28: 348-368.
27. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007; 52: 503-522. (Pubitemid 47268546)
28. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1992; 89: 9991-9995.
29. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 2002; 240: 42-48. (Pubitemid 36075572)
30. Bakri SJ, Couch SM, McCannel CA, Edwards AO. Sameday triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009; 29: 573-578.
31. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140.
32. Ehmann D, Garcia R. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Can J Ophthalmol 2010; 45: 36-40.
33. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 1974; 92: 149-154.
34. Francis BA, Chang EL, Haik BG. Particle size and drug interactions of injectable corticosteroids used in ophthalmic practice. Ophthalmology 1996; 103: 1884-1888. (Pubitemid 26403744)
35. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, ChuaWet al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular agerelated macular degeneration: one-year results. Arch Ophthalmol 2003; 121: 667-673. (Pubitemid 36554469)
36. Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye (Lond) 2005; 19: 163-170. (Pubitemid 40326161)
37. Jonas JB, Kreissig I, Degenring RF. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration. Br J Ophthalmol 2004; 88: 1557-1562. (Pubitemid 39573597)
38. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-250. (Pubitemid 30436775)
39. Jonas JB, Spandau UH, Kamppeter BA, Harder B. Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Eye (Lond) 2007; 21: 387-394. (Pubitemid 46358803)
40. Gilson MM, Bressler NM, Jabs DA, Solomon SD, Thorne JE, Wilson DJ. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 2007; 114: 1713-1721.
41. Lee J, Freeman WR, Azen SP, Chung EJ, Koh HJ. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina 2007; 27: 1205-1213. (Pubitemid 350211526)
42. Nicolo M, Ghiglione D, Lai S, Calabria G. Intravitreal triamcinolone in the treatment of serous pigment epithelial detachment and occult choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 2005; 15: 415-419. (Pubitemid 40943944)
43. Jonas JB, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Libondi T et al. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic Res 2009; 41: 21-27.
44. Agurto-Rivera R, Diaz-Rubio J, Torres-Bernal L, Macky TA, Colina-Luquez J, Papa-Oliva G et al. Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study (ISRCTN74123635). BMC Ophthalmol 2005; 5: 27.
45. Weber U. Exsudative AMD: regression analysis of transpupillary thermotherapy with and without intravitreal injection of triamcinolone, bevacizumab and ranibizumab. Klin Monbl Augenheilkd 2010; 227(11): 897-904.
46. Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology 2007; 114: 2183-2189. (Pubitemid 350181099)
47. Chan A, Blumenkranz MS, Wu KH, Wang G, Berker N, Parast LM et al. Photodynamic therapy with and without adjunctive intravitreal triamcinolone acetonide: a retrospective comparative study. Ophthalmic Surg Lasers Imaging 2009; 40: 561-569.
48. Hatta Y, Ishikawa K, Nishihara H, Ozawa S, Ito Y, Terasaki H. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography. Retina 2010; 30: 495-502.
49. Lie S, Aue A, Sacu S, Simader C, Polak K, Schmidt-Erfurth U. Time-course and characteristic morphology of retinal changes following combination of verteporfin therapy and intravitreal triamcinolone in neovascular age-related macular degeneration. Acta Ophthalmol 2010; 88: 212-217.
50. Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina 2007; 27: 458-461. (Pubitemid 46624286)
51. el Matri L, Chebil A, Kort F, Bouraoui R, Baklouti K, Mghaieth F. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010; 248: 779-784.
52. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008; 115: 2199-2205.
53. Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol 2009; 93: 754-758.
54. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301-304. (Pubitemid 40202568)
55. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122: 336-340. (Pubitemid 38314193)
56. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-598. (Pubitemid 41108858)
57. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal antiinflammatory drugs in ophthalmology. Surv Ophthalmol 2010; 55: 108-133.
58. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 2S-8S; discussion 21S-22S. (Pubitemid 28186987)
59. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120. (Pubitemid 28231490)
60. Botting RM. Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep 2010; 62: 518-525.
61. Maloney SC, Fernandes BF, Castiglione E, Antecka E, Martins C, Marshall JC et al. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina 2009; 29: 176-180.
62. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000; 24: 357-370. (Pubitemid 30367882)
63. Chakraborti AK, Garg SK, Kumar R, Motiwala HF, Jadhavar PS. Progress in COX-2 inhibitors: a journey so far. Curr Med Chem 2010; 17: 1563-1593.
64. Ku EC, Lee W, Kothari HV, Scholer DW. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med 1986; 80: 18-23. (Pubitemid 16067987)
65. Christen WG, Glynn RJ, Chew EY, Buring JE. Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women. Ophthalmology 2009; 116: 2386-2392.
66. McGeer PL, Sibley J. Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiol Aging 2005; 26: 1199-1203. (Pubitemid 40726013)
67. Libondi T, Jonas JB. Topical nepafenac for treatment of exudative age-related macular degeneration. Acta Ophthalmol 2010; 88: e32-e33.
68. Zweifel SA, Engelbert M, Khan S, Freund KB. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina 2009; 29: 1527-1531.
69. Boyer DS, Beer PM, Joffe L, Koester JM, Marx JL, Weisberger A et al. Effect of adjunctive diclofenac with verteporfin therapy to treat choroidal neovascularization due to age-related macular degeneration: phase II study. Retina 2007; 27: 693-700. (Pubitemid 47051764)
70. ClinicalTrials.gov identifier: NCT00805233. Combination ranibizumab and bromfenac for neovascular age-related macular degeneration. 2009 Available at http://www.clinicaltrials.gov/ct2/show/NCT00805233. Accessed 9 October 2010.
71. Baranano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol 2009; 93: 1387-1390.
72. Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 2010; 30: 509-515.
73. Snir M, Axer-Siegel R, Friling R, Weinberger D. Efficacy of diclofenac versus dexamethasone for treatment after strabismus surgery. Ophthalmology 2000; 107: 1884-1888.
74. Komarowska I, Heilweil G, Rosenfeld PJ, Perlman I, Loewenstein A. Retinal toxicity of commercially available intravitreal ketorolac in albino rabbits. Retina 2009; 29: 98-105.
75. Pe'er J, Hochberg FH, Foster CS. Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm 2009; 17: 299-306.
76. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-822. (Pubitemid 15104774)
77. Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fernandez P, Cronstein BN. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase: findings in a study of ecto-50-nucleotidase gene-deficient mice. Arthritis Rheum 2007; 56: 1440-1445. (Pubitemid 46764071)
78. Phillips DC, Woollard KJ, Griffiths HR. The antiinflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003; 138: 501-511. (Pubitemid 36269490)
79. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57: 163-172. (Pubitemid 41043882)
80. Kurup SK, Gee C, Greven CM. Intravitreal methotrexate in therapeutically resistant exudative age-related macular degeneration. Acta Ophthalmol 2010; 88: e145-e146.
81. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807-826. (Pubitemid 32295062)
82. Zohlnhofer D, Nuhrenberg TG, Neumann FJ, Richter T, May AE, Schmidt R et al. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. Mol Pharmacol 2004; 65: 880-889. (Pubitemid 38420493)
83. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262.
84. Attur MG, Patel R, Thakker G, Vyas P, Levartovsky D, Patel P et al. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res 2000; 49: 20-26. (Pubitemid 30073182)
85. Shanmuganathan VA, Casely EM, Raj D, Powell RJ, Joseph A, Amoaku WM et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005; 89: 666-669. (Pubitemid 40780569)
86. Nussenblatt RB, Byrnes G, Nida H, Yeh S, Faia L, Meyerle C et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010; 30(10): 1579-1587.
87. ClinicalTrials.gov identifier: NCT00766649. Sirolimus to treat geographic atrophy associated with age-related macular degeneration. 2010. Available at http://www.clinicaltrial.gov/ct2/show/NCT00766649. Accessed 9 October 2010.
88. ClinicalTrials.gov identifier: NCT00304954. Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration. 2010. Available at http://www.clinicaltrial.gov/ct2/show/NCT00304954. Accessed 9 October 2010.
89. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11: 180-210.
90. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol 2005; 139: 537-540. (Pubitemid 40379086)
91. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009; 147: 825-830, 830 e821.
92. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina 2010; 30: 71-80.
93. ClinicalTrials.gov identifier: NCT00695682. Intravitreal infliximab for diabetic macular edema (DME) and choroidal neovascularization (CNV) (ITVR). 2008. Available at http://www.clinicaltrial.gov/ct2/show/NCT00695682. Accessed 9 October 2010.
94. ClinicalTrials.gov identifier: NCT01136252. Intravitreal adalimumab in patients with choroidal neovascularization secondary to age-related macular degeneration. 2010. Available at http://www.clinicaltrial.gov/ct2/show/ NCT01136252. Accessed 9 October 2010.
95. Mikuls TR, Weaver AL. Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep 2003; 5: 270-277.
96. Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res 2009; 28: 117-144.
97. Goebel J, Stevens E, Forrest K, Roszman TL. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl Immunol 2000; 8: 153-159. (Pubitemid 32012382)
98. McDyer JF, Li Z, John S, Yu X, Wu CY, Ragheb JA. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol 2002; 169: 2736-2746. (Pubitemid 34921023)
99. Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005; 112: 764-770. (Pubitemid 40631493)
100. Mottershead M, Neuberger J. Daclizumab. Expert Opin Biol Ther 2007; 7: 1583-1596. (Pubitemid 47603083)
101. Jha P, Bora PS, Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol 2007; 44: 3901-3908. (Pubitemid 47337119)
102. Gehrs KM, Jackson JR, Brown EN,Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol 2010; 128: 349-358.
103. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007; 25: 1265-1275. (Pubitemid 350089828)
104. ClinicalTrials.gov identifier: NCT00935883. Complement inhibition with eculizumab for the treatment of nonexudative macular degeneration (AMD) (COMPLETE). 2009. Available at http://www.clinicaltrial.gov/ct2/show/ NCT00935883. Accessed 9 October 2010.
105. ClinicalTrials.gov identifier: NCT00473928. Safety of intravitreal POT-4 therapy for patients with neovascular age-related macular degeneration (AMD) (ASaP). 2010. Available at http://www.clinicaltrial.gov/ct2/show/NCT00473928. Accessed 9 October 2010.
106. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004; 137: 496-503. (Pubitemid 38328642)
107. Miller JW. Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis). Trans Am Ophthalmol Soc 2008; 106: 357-382.